Drug profile · INN
tenofovir disoproxil + emtricitabine
CIPLA TENOFOVIR + EMTRICITABINE 300/200
tenofovir disoproxil + emtricitabine (CIPLA TENOFOVIR + EMTRICITABINE 300/200) is an FDA-listed pharmaceutical active ingredient. Associated with Cipla Australia Pty Ltd.
Drug details — tenofovir disoproxil + emtricitabine
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
tenofovir disoproxil + emtricitabine (CIPLA TENOFOVIR + EMTRICITABINE 300/200) is an FDA-listed pharmaceutical active ingredient. Associated with Cipla Australia Pty Ltd.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is tenofovir disoproxil + emtricitabine?
tenofovir disoproxil + emtricitabine (CIPLA TENOFOVIR + EMTRICITABINE 300/200) is an FDA-listed pharmaceutical active ingredient. Associated with Cipla Australia Pty Ltd.
What is the brand name for tenofovir disoproxil + emtricitabine?
CIPLA TENOFOVIR + EMTRICITABINE 300/200 is a marketed brand name for tenofovir disoproxil + emtricitabine. Check FDA Drugs@FDA for the current US label holder and prescribing information.